Analyzing Klotho Neurosciences (NASDAQ:KLTO) & Kymera Therapeutics (NASDAQ:KYMR)

Klotho Neurosciences (NASDAQ:KLTO) and Kymera Therapeutics (NASDAQ:KYMR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, earnings, dividends and profitability.

Insider & Institutional Ownership

20.1% of Klotho Neurosciences shares are owned by institutional investors. 26.7% of Klotho Neurosciences shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for Klotho Neurosciences and Kymera Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Klotho Neurosciences	0	0	0	0	0.00
Kymera Therapeutics	0	4	12	1	2.82

Kymera Therapeutics has a consensus target price of $55.25, suggesting a potential upside of 83.37%. Given Kymera Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Klotho Neurosciences.

Volatility & Risk

Klotho Neurosciences has a beta of -1.1, indicating that its stock price is 210% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500.

Valuation and Earnings

This table compares Klotho Neurosciences and Kymera Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Klotho Neurosciences	N/A	N/A	$1.35 million	($0.36)	-0.50
Kymera Therapeutics	$58.89 million	33.32	-$146.96 million	($3.10)	-9.72

Klotho Neurosciences has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Klotho Neurosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Klotho Neurosciences and Kymera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Klotho Neurosciences	N/A	N/A	-25.89%
Kymera Therapeutics	-191.26%	-24.96%	-20.27%

About Klotho Neurosciences

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

About Kymera Therapeutics

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.